Research Article

In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer’s Disease

Tzu-Chieh Hung,1 Tung-Ti Chang,2 Ming-Jen Fan,3,4 Cheng-Chun Lee,5 and Calvin Yu-Chian Chen1,5

1 Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2 School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
3 Department of Biotechnology, Asia University, Taichung 41354, Taiwan
4 Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan
5 School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan

Correspondence should be addressed to Ming-Jen Fan; mjfan@asia.edu.tw and Calvin Yu-Chian Chen; ycc929@mit.edu

Received 21 October 2013; Revised 3 January 2014; Accepted 3 January 2014; Published 12 May 2014

Academic Editor: Fuu-Jen Tsai

Copyright © 2014 Tzu-Chieh Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer's disease (AD) is caused by the hyperphosphorylation of Tau protein aggregation. FKBP52 (FK506 binding protein 52) has been found to inhibit Tau protein aggregation. This study found six different kinds of anthocyanins that have high binding potential. After analyzing the docking positions, hydrophobic interactions, and hydrogen bond interactions, several amino acids were identified that play important roles in protein and ligand interaction. The proteins’ variation is described using eigenvectors and the distance between the amino acids during a molecular dynamics simulation (MD). This study investigates the three loops based around Glu85, Tyr113, and Lys121—all of which are important in inducing FKBP52 activation. By performing a molecular dynamic simulation process between unbound proteins and the protein complex with FK506, it was found that ligand targets that docked onto the FK1 domain will decrease the distance between Glu85/Tyr113 and Glu85/Lys121. The FKBP52 structure variation may induce FKBP52 activation and inhibit Tau protein aggregation. The results indicate that anthocyanins might change the conformation of FKBP52 during binding. In addition, the purple anthocyanins, such as cyanidin-3-glucoside and malvidin-3-glucoside, might be better than FK506 in regulating FKBP52 and treating Alzheimer's disease.

1. Introduction

Alzheimer’s disease (AD) is an irreversible degenerative disease of the brain. As time passes, a patient’s memory, language, intelligent judgment, and motor skills will gradually deteriorate. In 2010, about 36 million people had AD worldwide [1], and the medical expenses incurred totaled approximately $604 billion [2]. Huge medical expenses are associated with AD, and since AD almost always occurs in people over 65 years old, this disease becomes a great social burden in an aging society.

Drugs for Alzheimer’s disease include cholinesterase inhibitors (such as Aricept (donepezil), Exelon (rivastigmine), and Reminyl (galantamine) [3]) and N-methyl D-aspartate (NMDA) antagonists Memantine (such as Witgen and Ebixa). These two categories [4–6] of drugs only slow down or ameliorate the symptoms but do not treat or prevent the disease [7]. Recent studies have found that the brains of AD patients appear to have protein aggregations that cause brain damage. Hyper-phosphorylated Tau protein aggregation is associated with AD and worsens the symptoms [8]. There are a lot of treatments based on gene, protein, enzyme, and pathway association with disease in recent years [9–14]. Thus, by expressing FKBP52, the aggregation of Tau protein could be inhibited [15], and such inhibition could form the basis for a treatment of Alzheimer’s disease [16].

FKBP52 belongs to the FK506-binding protein family, which has a peptidyl prolyl isomerase (PPlase) functional domain. This domain will modify amino acids sites 231 and 255 of the Tau protein and make the Tau protein more readily phosphorylated [17]. An immunosuppressive drug containing FK506 could bind in this domain and inhibit
Figure 1: The disorder prediction and binding site detection. The blue curve in figure is the disorder disposition of each amino acid, the red lines indicate the residues of the important amino acids, and the purple region is the docking region, FK1 domain. The green regions of the amino-acid sequence show the predicted disordered regions, and the yellow regions, with the amino-acids noted in red mean important amino acids.

PPIase activity [18]. FKBP52 could bind with steroid receptors in FKBP12 domain 1 (FK1), a FKBP12 domain 2 (FK2), a C-terminal tetratricopeptide repeat domain (TPR), and a calmodulin binding domain. The FK1 domain has a proline-rich loop, which is the PPIase activity domain. Therefore, the FK1 domain is the immunosuppressant binding site of FKBP52. Although the sequence of the FK2 domain is similar to the sequence of FK1, this domain lacks PPIase activity and cannot interact with FK506. The TPR domain helps FKBP52 bind heat-shock protein 90 (HSP90) as a co-chaperone to remove Tau. Finally, the calmodulin-binding domain can regulate the phosphorylation of the protein [18, 20, 21].

Several studies have demonstrated that since the FK1 domain can bind PPIase, PPIase cannot modify Tau protein. Consequently, the calcineurin function will decrease, and Tau protein phosphorylation will be inhibited [22–27]. Furthermore, FKBP52 will have a higher binding affinity for HSP90 and steroid receptors (which could act as a co-chaperone [28, 29]) than FKBP51, which has a similar structure to FKBP52 and can make microtubules more stable [20, 30]. Therefore, this co-chaperone can bring about Tau protein degradation [31, 32]. The ligand binds the FK1 domain, activates FKBP52, and reduces Tau protein phosphorylation while removing abnormal Tau proteins, thus preventing AD [18].

Anthocyanidins are a family of vegetable flavonoids and are the primary components in producing plant color and are well-known water-soluble dyes. The six common kinds of anthocyanidin are pelargonidin (red-orange), peonidin (red), delphinidin, cyanidin, petunidin, and malvidin (different shades of purple) [33–35]. This study used delphinidin-3-glucoside (D3G), petunidin-3-glucoside (Pt3G), cyanidin-3-glucoside (C3G), malvidin-3-glucoside (M3G), peonidin-3-glucoside (P3G), and pelargonidin-3-glucoside (Pa3G) as test compounds. In recent years, it has been found that anthocyanins can regulate immunity [36], have anticancer [37–40] and anti-inflammatory properties [41], as well as having preventative functions in cardiovascular disease [42–44] and diabetes [45, 46]. In addition, they are antioxidants [47–51], have skin brightening properties [52–55], can aid erection [56], and contain many other health benefits. The current literature indicates that the antioxidant capacity of anthocyanins can prevent the deterioration of beta-amyloid protein type AD [57–60].

The Computer-Aided Drug Design (CADD) is an in silico simulation technique containing structure-based and
Figure 2: The structure of the ligand with (a) FK506 and (b) to (g) is D3G, Pt3G, C3G, M3G, P3G, and Pa3G, respectively, with the blue color indicating the differences.
ligand-based simulation. The main aspects of structure-based simulation are molecular docking, and molecular dynamics. The protein-ligand interactions could be analyzed by the above technique [61–63].

In this study, FK506, an efficacy drug [27, 64–68] with associated side effects [69–73], is used as a control drug. Our purpose is to determine whether anthocyanins influence FKBP52 activation, leading to the reduction of hyper-phosphorylated Tau protein aggregations, and thereby relieving Alzheimer’s disease. To analyze the effects of the different anthocyanins on FKBP52 activation, we will observe the transformation of the FKBP52 structure after binding and molecular dynamic simulation.

Recently report, the personalized medicine and biomedicine are necessary [74, 75] especially in rare diseases [76] and diagnosis [77]. The TCM is a famous personalized medicine. In order to compare the effect on FKBP52 with the anthocyanins and the compounds of Traditional Chinese Medicine (TCM), we screened the TCM Database@Taiwan (http://tcm.cmu.edu.tw/) for simultaneous docking. The TCM Database@Taiwan [78] contains 61,000 TCM compounds and is the largest TCM database in the world. Recently, TCM
Figure 4: Continued.
Figure 4: Ligplot illustrating protein-ligand interactions during docking. (a) FK506 and (b) to (g) indicate D3G, Pt3G, C3G, M3G, P3G, and Pa3G, respectively. Hydrophobic interactions are expressed by red spokes radiating towards the ligand atoms they contact in diagrams. Ligands are represented in purple. C, N, and O atoms are indicated in black, blue, and red, respectively.

Figure 5: Measured trajectories during 20 ns MD. (a) Complex, (b) ligand, and (c) total energy during MD.
Figure 6: Continued.
database applied for stroke prevention [79], inflammation inhibition [80], pain regulation [81], cancer receptor inhibition [82, 83], and virus prevention [84, 85] by CADD and cloud-computing web server [86]. Thus, using CADD to analyze protein-ligand interaction is feasible in the research.

2. Materials and Methods

2.1. Data Collection. The FKBP52 protein structure was downloaded from the Protein Data Bank (PDB: 1Q1C) [87]. 1Q1C is the crystal structure of FKBP52 from amino acids 21 to 257. This structure includes the FK1 domain (amino acids 33 to 139) and the FK2 domain (amino acids 151 to 254). Current literature identifies the FK1 domain as the PPlase functional site and the FK506 binding site which is the FKBP52 activation site. Therefore, the FK1 domain is the binding site that detects the compounds of Traditional Chinese Medicine, by comparison with the control drug FK506. The six common anthocyanins are D3G, Pt3G, C3G, M3G, P3G, and Pa3G; their compounds and structures can be obtained from Pubchem [88].

2.2. Disorder Protein Detection. Disordered proteins are important in drug design, and thus protein structure and the
Figure 7: The PCA-eigenvector between ligand and unbound protein. The projection to the first two PCA-eigenvectors as $X, Y$ axes based on the backbone of FKBP52 256 amino acids of MD is shown at the bottom of Figures 7(a) to 7(f). The red color indicates unbound protein and the blue is FKBP52 with ligand. The ligands in Figures 7(a) to 7(f) are FK506, C3G, D3G, M3G, Pa3G, and Pt3G.

ligand-interacting docking site should be detected [89, 90]. The protein sequence of CYP2C9 submitted to the Database of Protein Disorder (DisProt, http://www.disprot.org/) could predict the disordered region. Based on the result, the structure of docking site and drug efficiency could be discussed.

2.3. Docking. The control drug FK506 and anthocyanins (acting as ligands) were docked to the FK1 domain by LigandFit [91]. LigandFit, a program within Discovery Studio 2.5 (DS 2.5), is a receptor-rigid docking algorithm that uses a Monte Carlo simulation to measure the engaged position and orientation of the ligand when it targets the receptor of a crystal structure. The results were ranked based on docking score to assess the compatibility of the ligand and FKBP52 (IQIC) crystal structure combination. If the ligand had a higher docking score than FK506, we could then use hydrophobic interaction analysis via Ligplot v.2.2.25 [92] to assess the interaction between ligand and protein amino acids.

2.4. Molecular Dynamics Simulation (MD). Molecular dynamics simulation (MD) is a Discovery Studio 2.5 program and the protocol used is CHARMM force field [93] with minimization, heating, equilibration, and production stages. The interval time of each step was 2fs in the force field. The Minimize stage utilized steepest descent [94] and conjugate gradient [95] to run the maximum 500 steps in two minimizations. Besides Minimizing, other stages were analyzed using the SHAKE algorithm. The system was heated from 50 K to 310 K gradually in the 50ps heating intervals and then subjected to the 200ps Balance period. Finally, a 20-nanosecond production period was used as a canonical ensemble—meaning that in all systems, $N$, $V$ (volume) and $T$ (temperature) were the same.

After obtaining results from the molecular dynamic simulation, the root mean square deviation (RMSD) of the protein-ligand complex and the value of total energy were calculated using Discovery Studio 2.5. We also used Discovery Studio 2.5 to detect the presence of hydrogen bonds between the protein and ligand (based on 2.5 Å distance) and calculated the torsion of the ligand structure during the molecular dynamics simulation. The H-bond occupancy was recorded in a table. OriginPro 8.5 used the RMSD, the value of total energy, and the torsion of ligand structure to analyze and draw diagrams.
Figure 8: Clustering the ligand-protein interaction. (a) Unbound protein, (b) FK506, and (c) to (h) are D3G, Pt3G, C3G, M3G, P3G, and Pa3G, respectively. The mainly green triangle in upper left expresses the stability of the system, with the greater variation in red. The mainly red triangle in the lower right indicates groups calculated by RMSD variation during MD.
The reference-identified eigenvector was used to represent the protein variation in protein interactions [96]. We calculated that the projection of the first two PCA (principal component analysis) eigenvectors would become the X and Y axes, based on the backbone of FKBP52’s 256 amino acids of the MD data, to analyze the protein variation. The comparison between an unbound protein and a complex of protein with a ligand can describe the protein-ligand interaction.

Finally, we finished clustering based on the RMSD variation with a lapse of time in the molecular dynamic simulation and a threshold to distinguish the structure group of data. We identified the structure calculated in the intermediate period of the last population as the stable structure to determine that the interaction has been completed and balanced. The results of clustering can help analyze the variation of FKBP52 (1Q1C) structure under Docking, MD 0 ns and stability stages.

3. Results and Discussions

3.1. The Detection of Disorder Protein. The disordered protein is an unstructured protein. The docking site consists of a disorder protein that will make the complex stabilize difficultly.
Figure 10: Continued.
The disordered regions are defined as the disposition greater than 0.5 (Figure 1). The purple region in Figure 1 is FK1 domain which has been defined functional site of FKBP52. This result indicates that the docking site and important amino acids do not consist of disorder protein. Thus, the disorder protein effect on our result is weak and the complex can stabilize.

3.2. Molecular Docking. The results show the six common anthocyanins and control drug FK506 docking to FKBP52 (Table 1) ranked from top to bottom based on the docking score. The docking scores for anthocyanins were about 1.5 to 2 times greater than those for FK506. This indicates that these ligands had a greater binding force than FK506 for the FK1 domain. We selected the results of screening the TCM database@Taiwan based on PLP1 and PLP2 being better than anthocyanin, and then ranked the docking score (Table 2). There were nine compounds over the threshold, even bisindolylpyrrole CPB-53-594-5 was better than the control in all conditions. Although we have these candidates, anthocyanin can be easily assimilated in the diet and does not have side effects.

Six anthocyanins as the ligands were arranged by differences in structure without taking into consideration the Cis and Trans isoforms which are shown in blue in Figure 2. Although their main structures are similar, the different branches ensure that their general structures do not overlap in the docking process (Figure 3). This result indicates that the ligands are not similar in docking with the same general structure and that it is helpful to analyze the interaction with different anthocyanins docking to FKBP52.

Through ligplot v.2.2.25, Lys121, Tyr113, Glu85, and Arg73 were found to have a high percentage of H-bond and hydrophobic interactions (Figure 4), thus suggesting that they are important amino acids in FKBP52. The functional regions of FKBP52 [21, 87, 97–99] are identified as two loops containing Tyr113, Glu85, and Arg73 and are different between FK1 and FK2. This could determine whether PPIase functions or not, and the loop containing Lys121 will have an influence on calcineurin activity; therefore, these loops play an important role in ligand and protein interactions.

3.3. Molecular Dynamics

3.3.1. RMSDs and Total Energy Trajectories. The data generated from molecular dynamics was analyzed for protein-ligand RMSD, ligand RMSD, and total energy of ligands-FKBP52 and unbound FKBP52 (Figure 5). This result shows that the total energy of unbound FKBP52 is the highest, with the complex of protein with FK506 being second, and with anthocyanins being the lowest. A lower total energy implies a more stable protein-ligand complex; this result indicates that anthocyanins bound to FKBP52 are more stable than FK506 or unbound proteins. In Figure 5, based on the gentle curve of the RMSD and the total energy, the low variation of protein-ligand interaction can be seen. This result shows that the interactions had been completed in 20 ns and that the data is credible for analysis.

![Figure 10: FKBP52 structure variation by anthocyanin target to FK1 domain. (a) D3G, (b) Pt3G, (c) C3G, (d) M3G, (e) P3G, and (f) Pa3G.](image-url)
The torsion in MD demonstrates that the base structure will set appropriate positions quickly, and thus interactions to change FKBP52 will only occur by a slight twist and offset. Figure 6 presents the selected ligands that were found to be suitable in MD.

The H-bond plays an important role in protein and ligand interaction. We calculate the H-bond frequency of 1,000 interactions (0.02 ns is recorded as one interaction per 20 ns MD) while each ligand interacts with FKBP52 (Table 3). After analyzing the protein and ligand interactions from the docking process, the hydrophobic interactions, and the MD data, the results indicate that the amino acids Glu85, Tyr113, Lys121, Asp68, and Arg73 of FKBP52 formed many H-bonds during protein and ligand interaction (Table 4). After calculating the H-bond occupation of 7,000 interactions recorded from the seven ligands (FK506 and six anthocyanins), the amino acids with the three highest times of H-bond occupation were Glu85 (3099 times), Tyr113 (2357 times), and Lys121 (2135 times) in FKBP52. These occupations are obviously higher than the top four Asp68 (1794 times), top 5 Arg73 (1422 times), and others. It is suggested that Glu85, Tyr113, and Lys121 are important in FKBP52.

According to the PCA-eigenvector of the FKBP52 backbone atoms of residues 21–257 (Figure 7) and the different distributions of the first eigenvector between control (blue) and unbound protein (red), FK506 is described as a ligand and made the first eigenvector distribution move left compared to unbound proteins, but their distributions are still similar. The results of C3G and M3G are similar to FK506. The direction of Pa3G and Pt3G first eigenvector distribution is from minus to plus and this direction is different from other ligands (which go from plus to minus). This shows that C3G and M3G may cause FKBP52 structural variations to be the same as FK506 when the protein and ligand interact. On the other hand, Pa3G and Pt3G may have different effects on FKBP52, especially out-lying data from the first eigenvector of 0–5 ns in MD.

After protein and ligand interactions were finished, suitable protein structures were determined at 20 ns MD based on the curve of RMSD and the flattening of the total energy variation. After clustering, the data generated from MD in the same group indicate that their RMSD variation and structure are similar. The data generated from the calculations of the median of the last group period could be identified as stable structures (Figure 8). The results of clustering displaying C3G as ligand have the lowest RMSD variation and form the smallest group (only two groups) among unbound FKBP52 and seven ligands. One group of C3G and FKBP52 interaction in MD occurs in only the first twenty-eight out of 1000 data points, the others consist of the second group. This result indicates that if C3G performs as a ligand, FKBP52 will become stable in 0.58 ns and maintain the stability of the structure. Taking an analysis of clustering, the structures become stable in order of speed: C3G > (unbound protein) > Pt3G > Pa3G > D3G > FK506 > P3G > M3G.

Different FKBP52 stable structures in the docking process, at zero ns in MD, are observed, and this variation could be a result of protein and ligand interactions. The divergence of FKBP52 protein structure during MD between unbound protein and FK506 as a ligand was found to contain four loops in the FK1 domain, with each of them containing Arg73, Glu85, Tyr113, and Lys121, which would change their position during the MD period.

The result of ligplot and H-bond analysis shows that Glu85, Tyr113, and Lys121 had a more functional effect than the other amino-acids of FKBP52. Some references identify the two loops containing Glu85 and Tyr113 as the difference between the FK1 and FK2 domains, which function in PPlase immunosuppressive drug binding [21, 87, 97–99]. The loop with Lys121 has an influence on calcineurin activity, and the amino PI19L of this loop is different in the FK1 domain between FKBP52 and FKBP51 [98]. Accordingly, it is feasible to describe the functional structure of FKBP52 by the distance variation of the three loops with Glu85, Tyr113, and Lys121, which would change their position during the MD period.

There were obvious variations in the amino centroid positions of Glu85, Tyr113, and Lys121. Variations were found in the distance between Glu85/Tyr113 and Glu85/Lys121 but not between Tyr113/Lys121 (<1 Å). It was found that the distance between Glu85/Tyr113 increased from 13.581 Å to

---

**Table 2: Screening the TCM database docking to FKBP52 for results better than those for anthocyanin. The data are ranked by Dock Score.**

| Name           | Herb                                  | Dock Score | -PLP1 | -PLP2 |
|----------------|---------------------------------------|------------|-------|-------|
| Saussureamine C| Saussurea lappa Clarke                | 189.618    | 51.33 | 44.96 |
| Chebulic acid  | Phyllanthus urinaria L                | 136.859    | 43.81 | 48.7  |
| Bisindolylpyrrole-3*| Lycogala epidendrum              | 134.391    | 47.57 | 45.78 |
| Nodiflorin A   | Lippia nodiflora (L.) L. C. Rich.    | 133.342    | 45.56 | 55.25 |
| Bisindolylpyrrole-5*| Lycogala epidendrum              | 130.369    | 60.11 | 61.34 |
| Shogasulfonic acid A | Celastrus paniculatus          | 128.547    | 58.33 | 55.43 |
| Tournefolic acid A | Salvia miltiorrhiza                | 124.716    | 45.92 | 50.98 |
| Flazin         | Delphinium omeiense                 | 124.406    | 44.33 | 53.84 |
| Phyllanthusi E | Melicope triphylla                  | 121.443    | 45.84 | 52.68 |
| 4-Gingesulfonic acid | Celastrus paniculatus          | 119.885    | 50.65 | 51.37 |
| FK506*         |                                       | 62.232     | 58.04 | 50.16 |

*Control.

*The bisindolylpyrrole-3 is bisindolylpyrrole CPB-53-594-3, and bisindolylpyrrole-5 is bisindolylpyrrole CPB-53-594-5.
Table 3: H-bond occupancy for FKBP (1Q1C) with six kinds of anthocyanin and FK506 for a simulation time of 20 ns.

| Name               | H-bond interaction | Occupancy |
|--------------------|--------------------|-----------|
| FK506              | Tyr113:HH/O9       | 3.70%     |
|                    | Tyr57:HH/O1        | 61.30%    |
|                    | Tyr57:HH/O2        | 0.30%     |
| Delphinidin-3-glucoside | Asp72:OD1/H37   | 3.00%     |
|                    | Asp68:OD1/H38      | 1.10%     |
|                    | Asp68:OD2/H38      | 0.20%     |
|                    | Glu85:O/H43        | 51.80%    |
|                    | Arg73:HH12/O7      | 99.40%    |
|                    | Lys121:HZ/O9       | 28.20%    |
|                    | Lys121:HZ2/O9      | 26.40%    |
|                    | Lys121:HZ3/O9      | 22.60%    |
| Petunidin-3-glucoside | Asp68:OD1/H45      | 2.80%     |
|                    | Phe67:O/H45        | 2.30%     |
|                    | Glu85:O/H56        | 100.00%   |
|                    | Arg73:HH21/O22     | 1.10%     |
|                    | Lys121:HZ1/O21     | 35.00%    |
|                    | Lys121:HZ2/O21     | 43.90%    |
|                    | Lys121:HZ3/O21     | 46.30%    |
|                    | Trp90:HE1/O9       | 92.60%    |
|                    | Tyr113:HH/O29      | 1.90%     |
|                    | Tyr113:HH/O32      | 98.00%    |
| Cyanidin-3-glucoside | Ser69:O/H39        | 97.80%    |
|                    | Tyr113:OH/H48      | 2.30%     |
|                    | Glu85:O/H49        | 55.20%    |
|                    | Prol20:O/H53       | 93.30%    |
|                    | Arg73:HE/O17       | 0.10%     |
|                    | Arg73:HH11/O17     | 16.40%    |
|                    | Tyr113:HH/O27      | 0.40%     |
|                    | Tyr57:HH/O27       | 2.40%     |
| Malvidin-3-glucoside | Tyr113:OH/H41      | 0.60%     |
|                    | Tyr113:OH/H58      | 5.50%     |
|                    | Glu85:O/H58        | 0.10%     |
|                    | Arg73:HH12/O22     | 0.30%     |
|                    | Arg73:HH21/O22     | 7.40%     |
|                    | Arg73:HH22/O22     | 0.10%     |
|                    | Tyr113:HH/O10      | 4.30%     |
|                    | Tyr113:HH/O32      | 1.10%     |
| Peonidin-3-glucoside | Tyr113:OH/H44      | 59.3%     |
|                    | Val86:O/H44        | 60.2%     |
|                    | Tyr113:OH/H52      | 57.7%     |
|                    | Val86:O/H52        | 4.1%      |
|                    | Glu85:O/H53        | 95.8%     |
|                    | Glu85:O/H54        | 2.3%      |
|                    | Arg73:HH12/O2      | 0.30%     |
|                    | Tyr113:HH/O29      | 0.30%     |
|                    | Tyr57:HH/O18       | 0.10%     |

Table 3: Continued.

| Name               | H-bond interaction | Occupancy |
|--------------------|--------------------|-----------|
| Pelargonidin-3-glucoside | Asp68:OD1/H39     | 89.40%    |
|                    | Asp68:OD2/H39      | 85.90%    |
|                    | Tyr113:OH/H48      | 0.10%     |
|                    | Glu85:O/H49        | 4.40%     |
|                    | Arg73:HH21/O17     | 0.50%     |
|                    | Arg73:HH22/O17     | 13.10%    |
|                    | Lys121:HZ1/O17     | 1.70%     |
|                    | Lys121:HZ2/O17     | 8.40%     |
|                    | Lys121:HZ3/O17     | 1.00%     |
|                    | Tyr113:HH/O27      | 0.50%     |
|                    | Tyr57:HH/O19       | 0.10%     |

H-bond occupancy cutoff: 2.5 Å.

In Table 3, H-bond occupancy for FKBP (1Q1C) with six kinds of anthocyanin and FK506 for a simulation time of 20 ns is presented. The table shows the H-bond occupancy for each interaction, with FK506 occupying 3.70% of Tyr113:HH/O9, 61.30% of Tyr57:HH/O1, and 0.30% of Tyr57:HH/O2. For Delphinidin-3-glucoside, Asp72:OD1/H37 has 3.00% occupancy, while Asp68:OD1/H38 has 1.10% and Asp68:OD2/H38 has 0.20% occupancy. Glu85:O/H43 has 51.80% occupancy, and Arg73:HH12/O7 has 99.40% occupancy. Lys121:HZ/O9 has 28.20% occupancy. For Petunidin-3-glucoside, Asp68:OD1/H45 has 2.80% occupancy, and Phe67:O/H45 has 2.30% occupancy. Glu85:O/H56 has 100.00% occupancy. Lys121:HZ1/O21 has 35.00% occupancy, and Lys121:HZ2/O21 has 43.90% occupancy. Lys121:HZ3/O21 has 46.30% occupancy. Trp90:HE1/O9 has 92.60% occupancy. Tyr113:HH/O29 has 1.90% occupancy. Tyr113:HH/O32 has 98.00% occupancy. For Cyanidin-3-glucoside, Ser69:O/H39 has 97.80% occupancy, Tyr113:OH/H48 has 2.30% occupancy. Glu85:O/H49 has 55.20% occupancy. Prol20:O/H53 has 93.30% occupancy. Arg73:HE/O17 has 0.10% occupancy. Arg73:HH11/O17 has 16.40% occupancy. Tyr113:HH/O27 has 0.40% occupancy. Tyr57:HH/O27 has 2.40% occupancy. For Malvidin-3-glucoside, Tyr113:OH/H41 has 0.60% occupancy, Tyr113:OH/H58 has 5.50% occupancy. Glu85:O/H58 has 0.10% occupancy. Arg73:HH12/O22 has 0.30% occupancy. Arg73:HH21/O22 has 7.40% occupancy. Arg73:HH22/O22 has 0.10% occupancy. Tyr113:HH/O10 has 4.30% occupancy. Tyr113:HH/O32 has 1.10% occupancy. For Peonidin-3-glucoside, Tyr113:OH/H44 has 59.3% occupancy. Val86:O/H44 has 60.2% occupancy. Tyr113:OH/H52 has 57.7% occupancy. Val86:O/H52 has 4.1% occupancy. Glu85:O/H53 has 95.8% occupancy. Glu85:O/H54 has 2.3% occupancy. Arg73:HH12/O2 has 0.30% occupancy. Tyr113:HH/O29 has 0.30% occupancy. Tyr57:HH/O18 has 0.10% occupancy.

4. Conclusions

This research shows that the structure generated from the largest number of a final clustering group can become a stable condition for the final structure. The function of the PPIase inhibition and the FKBP52 activation can be suggested...
Table 4: Summary of interaction type, location, and frequency of test ligands following docking and MD simulation.

| Ligand      | Glu85 | Tyr113 | Lys121 | Asp68 | Arg73 | Ser69 | Pro120 | Trp90 | Val86 | Tyr57 |
|-------------|-------|--------|--------|-------|-------|-------|--------|-------|-------|-------|
| FK506 docking |       |        |        |       |       |       |        |       |       |       |
| FK506 ligplot | Y     |        |        |       |       |       | Y      |       |       |       |
| FK506 MD     |       | H      |        |       |       |       | Y      |       |       |       |
| D3G docking  |       |        |        |       |       |       |        |       |       |       |
| D3G ligplot  | H     |        |        |       |       | Y     |        |       |       |       |
| D3G MD       | H     |        | HHH    |       |       | HH    |        |       |       |       |
| Pt3G docking |       |        |        |       |       | Y     |        |       |       |       |
| Pt3G ligplot | H     |        | H      |       |       | Y     |        |       |       |       |
| Pt3G MD      | H     | HH     | HHH    | H     |       |       |        |       |       |       |
| C3G docking  |       |        |        |       |       | HH    |        |       |       |       |
| C3G ligplot  | H     |        | H      | Y     |       |       | H      |       |       |       |
| C3G MD       | H     | HH     | HHH    | HH    | H     |       |        |       |       |       |
| M3G docking  |       |        |        |       |       |       |        |       |       |       |
| M3G ligplot  | H     |        | H      |       | Y     | Y     | Y      |       |       |       |
| M3G MD       | H     | HH     | HHH    | H     | H     |       |        |       |       |       |
| Pt3G docking |       |        |        |       |       | Y     |        |       |       |       |
| Pt3G ligplot | H     |        | H      |       | Y     | Y     | Y      |       |       |       |
| Pt3G MD      | H     | HH     | HHH    | HH    | H     |       |        |       |       |       |
| Pa3G docking |       |        |        |       |       | H     |        |       |       |       |
| Pa3G ligplot | H     | HH     | H      |       |       | Y     |        |       |       |       |
| Pa3G MD      | H     | HH     | HHH    | HH    | HH    | HH    |       |       |       |       |

* Each letter denotes one interaction. 

π: pi-interaction.
Y: Hydrophobic interaction.
H: H-bond.

Table 5: Comparing amino distance variation from Lys121 to Glu85 while the protein is in an unbound condition and targets the ligand during docking and MD.

| Ligand      | Docking 0 ns | Stable | 20 ns |
|-------------|--------------|--------|-------|
|             | 121/85       | 121/85 | 121/85 |
| Unbound     | 20.783       | 19.916 | 20.215 |
| 506         | 19.162       | 18.861 | 17.990 |
| D3G         | 19.162       | 18.327 | 15.450 |
| Pt3G        | 19.162       | 19.597 | 19.111 |
| C3G         | 19.162       | 16.356 | 16.033 |
| M3G         | 19.162       | 17.792 | 16.487 |
| P3G         | 19.162       | 17.714 | 17.519 |
| Pa3G        | 19.162       | 18.642 | 18.078 |
| Anthocyanin | 19.162       | 18.071 | 17.134 |

Table 6: Comparing amino-acid distance variation from Tyr113 to Glu85 while the protein is in an unbound condition and targets the ligand during docking and MD.

| Ligand      | Docking 0 ns | Stable | 20 ns |
|-------------|--------------|--------|-------|
|             | 113/85       | 113/85 | 113/85 |
| Unbound     | 13.581       | 11.994 | 11.690 |
| 506         | 13.306       | 11.335 | 11.626 |
| D3G         | 13.306       | 11.276 | 10.972 |
| Pt3G        | 13.306       | 12.817 | 11.698 |
| C3G         | 13.306       | 11.276 | 10.945 |
| M3G         | 13.306       | 12.817 | 10.941 |
| P3G         | 13.306       | 12.795 | 11.735 |
| Pa3G        | 13.306       | 12.817 | 10.941 |
| Anthocyanin | 13.306       | 11.979 | 11.320 |

Anthocyanin average: 13.306 ± 1.327
according to the variation of Glu85/Tyr113, and Glu85/Lys121 indicates the FKBP52 structural variation. Anthocyanins might regulate FKBP52 to prevent Alzheimer’s disease based on the structure variation of FKBP52, especially the purple anthocyanins C3G and M3G. According to these results, these two anthocyanins could be predicted to have a better effect than the others. Due to their greater efficiency and fewer side effects, anthocyanins may become a more appropriate medicine than FK506.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Authors’ Contribution**

Tzu-Chieh Hung and Tung-Ti Chang contributed equally to this paper.

**Acknowledgments**

This research was supported by Grants from the National Science Council of Taiwan (NSC102-2313-B-468-001, NSC102-2325-B039-001, NSC102-2221-E-468-027-), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, 102-ASIA-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03). The authors are grateful to Weng Leong Tou, Kuan-Chung Chen, and Hung-Jin Huang for their help in this research, and to Christine Quan for the help in translation correction. Finally, our gratitude goes to Tim Williams, Asia University.

**References**

[1] Alzheimer’s Disease International, World Alzheimer Report 2009, 2009, http://www.alz.co.uk/research/world-report.

[2] A. Wimo and M. Prince, World Alzheimer Report 2010: The Global Economic Impact of Dementia, 2010, http://www.alz.co.uk/research/world-report-2012.

[3] N. A. Clarke and P. T. Francis, “Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy,” Expert Review of Neurotherapeutics, vol. 5, no. 5, pp. 671–682, 2005.

[4] T. Voisin and B. Vellas, “Diagnosis and treatment of patients with severe Alzheimer’s disease,” Drugs and Aging, vol. 26, no. 2, pp. 135–144, 2009.

[5] C. Bablioni, C. Del Percio, R. Bordet et al., “Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients,” Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology, vol. 124, no. 5, pp. 837–850, 2013.

[6] P. T. Francis, M. J. Ramirez, and M. K. Lai, “Neurochemical basis for symptomatic treatment of Alzheimer’s disease,” Neuropharmacology, vol. 59, no. 4–5, pp. 221–229, 2010.

[7] F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto, “Alzheimer’s disease: clinical trials and drug development,” The Lancet Neurology, vol. 9, no. 7, pp. 702–716, 2010.

[8] C. Duyckaerts, B. Delatour, and M. Potier, “Classification and basic pathology of Alzheimer disease,” Acta Neuropathologica, vol. 118, no. 1, pp. 5–36, 2009.

[9] D.-Y. Lin, F.-J. Tsai, C.-H. Tsai, and C.-Y. Huang, “Mechanisms governing the protective effect of 17β-estradiol and estrogen receptors against cardiomyocyte injury,” Biomedicine, vol. 1, no. 1, pp. 21–28, 2011.

[10] C.-C. Lee, C.-H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013.

[11] C.-H. Wang, W.-D. Lin, D.-T. Bau et al., “Appearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathway,” BioMedicine, vol. 3, no. 2, pp. 82–87, 2013.

[12] Y.-M. Chang, B. K. Velmurugan, W.-W. Kuo et al., “Inhibitory effect of alpinate Oxyphylla fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells,” BioMedicine, vol. 3, no. 4, pp. 148–152, 2013.

[13] I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Association analysis between Tourette’s syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children,” BioMedicine, vol. 3, no. 2, pp. 88–91, 2013.

[14] W.-Y. Lin, H.-P. Liu, J.-S. Chang et al., “Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurism formation,” BioMedicine, vol. 3, no. 2, pp. 73–81, 2013.

[15] B. Chambraud, E. Sardin, J. Giustiniani et al., “A role for FKBP52 in Tau protein function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 6, pp. 2658–2663, 2010.

[16] J. Giustiniani, M. Sineus, E. Sardin et al., “Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer’s disease and FTDP-17,” Journal of Alzheimer’s Disease, vol. 29, no. 2, pp. 471–483, 2012.

[17] J. Koren III, U. K. Jinwal, Z. Davey, J. Kiray, K. Arulselvam, and C. A. Dickey, “Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies,” Molecular Neurobiology, vol. 44, no. 1, pp. 65–70, 2011.

[18] W. Cao and M. Konsolaki, “FKBP immunophilins and Alzheimer’s disease: a chaperoned affair,” Journal of Biosciences, vol. 36, no. 3, pp. 493–498, 2011.

[19] C. L. Storer, C. A. Dickey, M. D. Galignana, T. Rein, and M. B. Cox, “FKBP51 and FKBP52 in signaling and disease,” Trends in Endocrinology and Metabolism, vol. 22, no. 12, pp. 481–490, 2011.

[20] B. Chambraud, H. Belabes, V. Fontaine-Lenoir, A. Fellous, and E. E. Baulieu, “The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation,” FASEB Journal, vol. 21, no. 11, pp. 2787–2797, 2007.

[21] T. H. Davies and E. R. Sánchez, “FKBP52,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 1, pp. 42–47, 2005.

[22] K. P. Lu, Y. Liou, and X. Z. Zhou, “Pinning down proline-directed phosphorylation signaling,” Trends in Cell Biology, vol. 12, no. 4, pp. 164–172, 2002.

[23] K. P. Lu and X. Z. Zhou, “The prolyl isomerase PInI: a pivotal new twist in phosphorylation signalling and disease,” Nature Reviews Molecular Cell Biology, vol. 8, no. 11, pp. 904–916, 2007.
B. Ruan, K. Pong, F. Jow et al., "Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 1, pp. 33–38, 2008.

J. Liu, J. D. Farmer Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes," *Cell*, vol. 66, no. 4, pp. 807–815, 1991.

C. R. Kissinger, H. E. Parge, D. R. Knighton et al., "Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex," *Nature*, vol. 378, no. 6557, pp. 641–644, 1995.

L. C. Reese, F. Laeza, R. Woltjer, and G. Taglialetela, "Dysregulated phosphorylation of Ca2+/calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease," *Journal of Neurochemistry*, vol. 119, no. 4, pp. 791–804, 2011.

T. H. Davies, Y. Ning, and E. R. Sánchez, "Differential control of glucocorticoid receptor hormone-binding function by tetra-trico-peptide repeat (TPR) proteins and the immunosuppressive ligand FK506," *Biochemistry*, vol. 44, no. 6, pp. 2030–2038, 2005.

M. D. Galigniana, A. G. Erlejman, M. Monte, C. Gómez-Sanchez, and G. Piwien-Pilipuk, "The hsp90-FKBP52 complex links the mineralocorticoid receptor to motors and persists bound to the receptor in early nuclear events," *Molecular and Cellular Biology*, vol. 30, no. 5, pp. 1285–1298, 2010.

D. L. Cioffi, T. R. Hubler, and J. G. Scammell, "Organization and function of the FKBP52 and FKBP51 genes," *Current Opinion in Pharmacology*, vol. 11, no. 4, pp. 308–313, 2011.

H. R. Quintá and M. D. Galigniana, "The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation," *British Journal of Pharmacology*, vol. 166, no. 2, pp. 637–649, 2012.

H. R. Quintá, D. Maschi, C. Gómez-Sanchez, G. Piwien-Pilipuk, and M. D. Galigniana, "Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth," *Journal of Neurochemistry*, vol. 115, no. 3, pp. 716–734, 2010.

A. Castañeda-Ovando, M. D. L. Pacheco-Hernández, M. E. Pérez-Hernández, J. A. Rodríguez, and C. A. Galán-Vidal, "Chemical studies of anthocyanins: a review," *Food Chemistry*, vol. 113, no. 4, pp. 859–871, 2009.

F. C. Stintzing and R. Carle, "Functional properties of anthocyanins and betalains in plants, food, and in human nutrition," *Trends in Food Science and Technology*, vol. 15, no. 1, pp. 19–38, 2004.

J. M. Kong, L. S. Chia, N. K. Goh, T. F. Chia, and R. Brouillard, "Analysis and biological activities of anthocyanins," *Phytochemistry*, vol. 64, no. 5, pp. 923–933, 2003.

S. S. Percival, "Grape consumption supports immunity in animals and humans," *Journal of Nutrition*, vol. 139, supplement 9, pp. 180S1–180S5, 2009.

C. Zhao, M. M. Giusti, M. Malik, M. P. Moyer, and B. A. Magnuson, "Effects of commercial anthocyanin-rich on colonic cancer and nontumorigenic colonic cell growth," *Journal of Agricultural and Food Chemistry*, vol. 52, no. 20, pp. 6122–6128, 2004.

J. W. Hyun and H. S. Chung, "Cyanidin and malvidin from Oryza sativa cv. heugjinjubyeo mediate cytotoxicity against human mononcytic leukemia cells by arrest of G 2/M phase and induction of apoptosis," *Journal of Agricultural and Food Chemistry*, vol. 52, no. 8, pp. 2213–2217, 2004.

H. Jin, Q. Leng, and C. Li, "Dietary flavonoid for preventing colorectal neoplasms," *Cochrane Database of Systematic Reviews*, vol. 8, Article ID CD009350, 2012.

H. P. Huang, Y. C. Chang, C. H. Wu, C. N. Hung, and C. Wang, "Anthocyanin-rich Mulberry extract inhibit the gastric cancer cell growth in vitro and xenograft mice by inducing signals of p38/p53 and c-jun," *Food Chemistry*, vol. 129, no. 4, pp. 1703–1709, 2011.

T. Tsuda, F. Horio, and T. Osawa, "Cyanidin 3-O-β-D-glucoside suppresses nitric oxide production during a zymosan treatment in rats," *Journal of Nutritional Science and Vitaminology*, vol. 48, no. 4, pp. 305–310, 2002.

X. Xia, W. Ling, J. Ma et al., "An anthocyanin-rich extract from black rice enhances atherosclerotic plaque stabilization in apolipoprotein E-deficient mice," *Journal of Nutrition*, vol. 136, no. 8, pp. 2220–2225, 2006.

A. Jennings, A. A. Welch, S. J. Fairweather-Tait et al., "Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women," *The American Journal of Clinical Nutrition*, vol. 96, no. 4, pp. 781–788, 2012.

S. S. Hassellund, A. Flaa, S. E. Kjeldsen et al., "Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study," *Journal of Human Hypertension*, vol. 27, no. 2, pp. 100–106, 2013.

D. Ghosh and T. Konishi, "Anthocyanins and anthocyanin-rich extracts: role in diabetes and eye function," *Asia Pacific Journal of Clinical Nutrition*, vol. 16, no. 2, pp. 200–208, 2007.

M. K. Kang, J. Li, J. L. Kim et al., "Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration," *American Journal of Physiology Renal Physiology*, vol. 303, no. 7, pp. F1060–F1069, 2012.

S. H. Nam, S. P. Choi, M. Y. Kang, H. J. Koh, N. Kozukue, and M. Friedman, "Antioxidative activities of bran extracts from twenty one pigmented rice cultivars," *Food Chemistry*, vol. 94, no. 4, pp. 613–620, 2006.

M. Philpott, K. S. Gould, C. Lim, and L. R. Ferguson, "In situ and in vitro antioxidant activity of sweetpotato anthocyanins," *Journal of Agricultural and Food Chemistry*, vol. 52, no. 6, pp. 1511–1513, 2004.

Y. Wang, X. Chen, Y. Zhang, and X. Chen, "Antioxidant activities and major anthocyanins of myrobalan plums (Prunus cerasifera Ehrh.)," *Journal of Food Science*, vol. 77, no. 4, pp. C388–C393, 2012.

S. J. Chen, J. G. Chung, Y. C. Chung, and S. T. Chou, "In vitro antioxidant and antiproliferative activity of the stem extracts from graptopetalum paraguayanum," *American Journal of Chinese Medicine*, vol. 36, no. 2, pp. 369–383, 2008.

Y. L. Ho, S. S. Huang, J. S. Deng, Y. Lin, Y. Chang, and G. Huang, "In vitro antioxidant properties and total phenolic contents of wetland medicinal plants in Taiwan," *Botanical Studies*, vol. 53, no. 1, pp. 55–66, 2012.

M. Miyazawa, T. Oshima, K. Koshio, Y. Itsuzaki, and J. Anzai, "Tyrosinase inhibitor from black rice bran," *Journal of Agricultural and Food Chemistry*, vol. 51, no. 24, pp. 6953–6956, 2003.

J. Yamakoshi, F. Otsuka, A. Sano et al., "Lightening effect on ultraviolet-induced pigmentation of Guinea pig skin by oral administration of a proanthocyanin-rich extract from grape seeds," *Pigment Cell Research*, vol. 16, no. 6, pp. 629–638, 2003.
Evidence-Based Complementary and Alternative Medicine

[54] C. Gómez-Cordovés, B. Bartolomé, W. Vieira, and V. M. Virador, "Effects of wine phenolics and sorghum tannins on tyrosinase activity and growth of melanoma cells," Journal of Agricultural and Food Chemistry, vol. 49, no. 3, pp. 1620–1624, 2001.

[55] H. M. Dell’Agli, G. V. Galli, U. Vrhovsek, F. Mattivi, and M. Hattori, E. Sugino, K. Minoura et al., "Different inhibitory model system? A genetic algorithm, support vector machine and molecular dynamics approach," BioMedicine, vol. 3, no. 2, p. 65, 2013.

[56] T. Ochiai, M. Nagata, K. Nakajima et al., "Investigation into potent inflammation inhibitors from traditional Chinese medicine," Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011.

[57] W. L. Liao and F.-J. Tsai, "Personalized medicine: a paradigm shift in healthcare," BioMedicine, vol. 3, no. 2, pp. 66–72, 2013.

[58] C. Y. Chen, "TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening In Silico," PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011.

[59] K. C. Chen and C. Y. C. Chen, "Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach," Soft Matter, vol. 7, no. 8, pp. 4001–4008, 2011.

[60] K. C. Chen, M. F. Sun, S. C. Yang et al., "Investigation into potent inflammation inhibitors from traditional Chinese medicine," Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011.

[61] W. I. Tou, S. S. Chang, C. C. Lee, and C. Y. Chen, "Drug design for neuropathic pain regulation from traditional Chinese medicine," Scientific Reports, vol. 3, p. 844, 2013.

[62] S. C. Yang, S. S. Chang, H. Chen, and C. Y. Chen, "Identification of potent EGFR inhibitors from TCM Database@Taiwan," PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011.

[63] C. Y. C. Chen, S. S. Chang, and C. Y. Chen, "Identifying HER2 inhibitors from natural products database," PLoS ONE, vol. 6, no. 12, Article ID e28793, 2011.

[64] S. S. Chang, H. J. Huang, and C. Y. Chen, "Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine," PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011.

[65] T. T. Chang, M. F. Sun, H. Y. Chen et al., "Screening from the world’s largest TCM database against H1N1 virus," Journal of Biomolecular Structure and Dynamics, vol. 28, no. 5, pp. 773–786, 2011.

[66] T. Y. Tsai, K. W. Chang, and C. Y. Chen, "iScreen: World’s first cloud–computing web server for virtual screening and de novo drug design based on TCM database@Taiwan," Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011.

[67] B. Wu, P. Li, Y. Liu et al., "3D structure of human FK506-binding protein 52: implication for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 22, pp. 8348–8353, 2004.
[88] Y. Wang, E. Bolton, S. Dracheva et al., “An overview of the PubChem BioAssay resource,” Nucleic Acids Research, vol. 38, no. 1, Article ID gkp965, pp. D255–D266, 2009.

[89] W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, vol. 19, no. 4, pp. 367–372, 2014.

[90] C. Y. C. Chen and W. L. Tou, “How to design a drug for the disordered proteins,” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013.

[91] C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” Journal of Molecular Graphics and Modelling, vol. 21, no. 4, pp. 289–307, 2003.

[92] R. A. Laskowski and M. B. Swindells, “LigPlot+: multiple ligand-protein interaction diagrams for drug discovery,” Journal of Chemical Information and Modeling, vol. 51, no. 10, pp. 2778–2786, 2011.

[93] B. R. Brooks, C. L. Brooks III, A. D. Mackerell Jr. et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009.

[94] R. Fletcher, Optimization, Academic Press, New York, NY, USA, 1969.

[95] R. Fletcher and C. M. Reeves, “Function minimization by conjugate gradients,” Computer Journal, vol. 7, no. 2, pp. 149–154, 1964.

[96] J. H. Peters and B. L. de Groot, “Ubiquitin dynamics in complexes reveal molecular recognition mechanisms beyond induced fit and conformational selection,” PLOS Computational Biology, vol. 8, no. 10, Article ID e1002704, 2012.

[97] P. Li, Y. Ding, B. Wu, C. Shu, B. Shen, and Z. Rao, “Structure of the N-terminal domain of human FKBP52,” Acta Crystallographica D: Biological Crystallography, vol. 59, no. 1, pp. 16–22, 2003.

[98] D. L. Riggs, M. B. Cox, H. L. Tardif, M. Hessling, J. Buchner, and D. F. Smith, “Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling,” Molecular and Cellular Biology, vol. 27, no. 24, pp. 8658–8669, 2007.

[99] C. R. Sinars, J. Cheung-Flynn, R. A. Rimerman, J. G. Scammell, D. F. Smith, and J. Clardy, “Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 868–873, 2003.